文献速递妇科

早期子宫透明细胞癌的临床病理特征与治疗:16年经验

Clinicopathologic features and treatment in patients with early stage uterine clear cell carcinoma: A 16-year experience.
PubMed 文献 · Gynecol Oncol · 2019-06-18

该回顾性研究纳入2000至2016年经中心病理确认的112例I或II期子宫透明细胞癌患者,分析临床病理因素及辅助治疗对无复发生存和总生存的影响。中位无复发生存4.32年,中位总生存9.8年;多因素分析显示年龄≥70岁和LVSI阳性与更短的无复发生存和总生存相关,辅助治疗类型未影响生存。

要点

  • 年龄≥70岁与更短的无复发生存(HR 2.48)和总生存(HR 3.57)相关。
  • LVSI阳性与更短的无复发生存(HR 2.19)和总生存(HR 2.46)相关。
  • 在该回顾性描述性非对照系列中,辅助治疗类型未影响无复发生存或总生存。

核心结论

  • 早期子宫透明细胞癌患者的总生存接近10年,年龄≥70岁患者无论治疗方式如何,无进展生存和总生存均更差,作者鼓励在选择辅助治疗时考虑生活质量影响。

研究设计与样本

  • 回顾性综述,纳入2000至2016年间治疗和/或随访的经中心病理确认的I或II期子宫透明细胞癌病例,包括纯或混合组织学中子宫透明细胞癌占比>50%者,共112例女性。

主要发现

  • 中位年龄65.5岁(范围34-94);混合型子宫透明细胞癌占61%,纯型占39%;IA期占66%,IB期占15%,II期占18%。
  • 辅助治疗包括化疗+放疗(26%)、近距离放疗(27%)、全盆腔放疗(15%)、单纯化疗(8%)和观察(24%)。
  • 38例(34%)女性出现复发;中位无复发生存4.32年(95%CI 2.77-5.78)。
  • 多因素分析中,年龄≥70岁(HR 2.48,95%CI 1.28-4.81)和LVSI阳性(HR 2.19,95%CI 1.15-4.18)与更短的无复发生存相关。
  • 中位总生存9.8年(95%CI 7.46-15.93);多因素分析中,年龄≥70岁(HR 3.57,95%CI 1.64-7.74)和LVSI阳性(HR 2.46,95%CI 1.12-5.37)与更短的总生存相关。

临床怎么用

  • 在该回顾性描述性非对照患者系列中,辅助治疗类型未影响无复发生存或总生存。
  • 作者认为,年龄≥70岁患者无论治疗方式如何无进展生存和总生存均更差,鼓励在选择辅助治疗时考虑生活质量影响。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate clinicopathologic factors and adjuvant treatment effects on recurrence free (RFS) and overall survival (OS) in early stage uterine clear cell carcinoma (UCCC). METHODS: Our retrospective review included central pathology confirmed stage I or II UCCC treated and/or followed between 2000 and 2016. Cases with pure or mixed histology with >50% UCCC were included. Data were analyzed using Kaplan-Meier method and Cox proportional hazards regressions. RESULTS: 112 women were identified. Median age was 65.5 years (range 34-94). Most patients had mixed UCCC (61%), while 39% had pure UCCC. The majority of patients had stage IA UCCC (66%) versus stage IB (15%) or stage II (18%) disease. Adjuvant treatment included chemotherapy + radiation (26%), brachytherapy (27%), whole pelvic radiation (15%), chemotherapy alone (8%), and observation (24%). Thirty-eight (34%) women had recurrent disease. Median RFS was 4.32 years (95% CI 2.77-5.78). On multivariate analysis, age ≥70 (HR 2.48, 95% 1.28-4.81) and positive LVSI (HR 2.19, 95% CI 1.15-4.18) were associated with shorter RFS. Median OS was 9.8 years (95% CI 7.46-15.93). On multivariate analyses, age ≥70 (HR 3.57, 95% CI 1.64-7.74) and positive LVSI (HR 2.46, 95% CI 1.12-5.37) were associated with shorter OS. In this retrospective descriptive uncontrolled patient series, adjuvant treatment type did not impact RFS or OS. CONCLUSIONS: OS approaches 10 years for early stage UCCC patients. Women ≥70 years have worse PFS and OS regardless of treatment modality, encouraging consideration of quality of life implications when electing for adjuvant therapy.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Armbruster SD, Previs R, Soliman PT, et al. Clinicopathologic features and treatment in patients with early stage uterine clear cell carcinoma: A 16-year experience. Gynecol Oncol. 2019. PMID: 31221496. doi:10.1016/j.ygyno.2019.06.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。